Cargando…

Expression of CD200 on AML blasts directly suppresses memory T-cell function

Detalles Bibliográficos
Autores principales:	Coles, S J, Hills, R K, Wang, E C Y, Burnett, A K, Man, S, Darley, R L, Tonks, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460216/ https://www.ncbi.nlm.nih.gov/pubmed/22430635 http://dx.doi.org/10.1038/leu.2012.77

Ejemplares similares

Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3(+) regulatory T cells
por: Coles, S J, et al.
Publicado: (2012)

Use of an anti‐CD200‐blocking antibody improves immune responses to AML in vitro and in vivo
por: Rastogi, Namrata, et al.
Publicado: (2020)

RUNX1–ETO deregulates the proliferation and growth factor responsiveness of human hematopoietic progenitor cells downstream of the myeloid transcription factor, MYCT1
por: Liddiard, K, et al.
Publicado: (2012)

Hemophagocytic Lymphohistiocytosis in RUNX1::RUNX1T1 Positive AML with Blast Count Below 20%
por: Huang, Xingqin, et al.
Publicado: (2023)

Successful re-treatment with azacitidine in a patient with low blast count AML transformed from MDS after suspension of this agent
por: Niscola, Pasquale, et al.
Publicado: (2015)

BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance
por: Weiland, J, et al.
Publicado: (2016)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

The prognostic significance of trisomy 4 in acute myeloid leukaemia is dependent on age and additional abnormalities
por: Chilton, L, et al.
Publicado: (2016)

CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML
por: Satlsar, Esmaeil Shahabi, et al.
Publicado: (2020)

Comment: In Response to “CD9 Is a Very Helpful Marker for Discriminating AML-M3 from HLA-DR-Negative Non-M3 AML”
por: Gajendra, Smeeta
Publicado: (2020)

Blast Injury of the Scrotum
por: Dubhashi, Siddharth Pramod, et al.
Publicado: (2020)

CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis
por: Morgan, Huw J., et al.
Publicado: (2022)

A genomic analysis of Philadelphia chromosome-negative AML arising in patients with CML
por: Krysiak, K, et al.
Publicado: (2016)

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
por: Herbrich, Shelley, et al.
Publicado: (2021)

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
por: Sekeres, Mikkael A., et al.
Publicado: (2021)

Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
por: Gadhoum, S Z, et al.
Publicado: (2016)

Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells
por: Mikhailova, Ekaterina, et al.
Publicado: (2021)

γ-Catenin is overexpressed in acute myeloid leukemia and promotes the stabilization and nuclear localization of β-catenin
por: Morgan, R G, et al.
Publicado: (2013)

Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Vacuolated Blasts in the Bone Marrow of a Child with Rhabdomyosarcoma
por: Ataseven, Eda, et al.
Publicado: (2020)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia
por: Haferlach, T, et al.
Publicado: (2016)

Correction: Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
Publicado: (2021)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

dsDNA from extracellular vesicles (EVs) in adult AML
por: Bernardi, Simona, et al.
Publicado: (2020)

The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy
por: Buckley, S A, et al.
Publicado: (2015)

Ocular surface burn secondary to smart phone battery blast
por: Narang, Purvasha, et al.
Publicado: (2017)

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone
por: Hahn, C N, et al.
Publicado: (2015)

Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT
por: Bohl, S, et al.
Publicado: (2016)

Isolated central nervous system blast crisis in a case of chronic myeloid leukemia on dasatinib
por: Kiran, P. K., et al.
Publicado: (2018)

CD69(+) memory T lymphocytes of the bone marrow and spleen express the signature transcripts of tissue‐resident memory T lymphocytes
por: Siracusa, Francesco, et al.
Publicado: (2019)

SparkBLAST: scalable BLAST processing using in-memory operations
por: de Castro, Marcelo Rodrigo, et al.
Publicado: (2017)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

Pseudo Chediak Higashi-like inclusions in myeloblasts in AML-M2
por: Sharma, Sunita, et al.
Publicado: (2013)

FACSorting help to analyze a rare case of acute myeloid leukemia with concurrent AML1‐ETO and PML‐RARA
por: Chen, Man, et al.
Publicado: (2021)

Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
por: Gangat, Naseema, et al.
Publicado: (2022)

Flagging performance of two automated hematology analyzers in blast cell screening
por: Zhang, Yang, et al.
Publicado: (2021)

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Upregulated TCRζ improves cytokine secretion in T cells from patients with AML
por: Chen, Shaohua, et al.
Publicado: (2015)

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML
por: Jasra, Sakshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4imef17o5jsuns19bclhcluati